Baird Maintains an 'Outperform' Rating on Affymax, Inc. (AFFY); Hematide US Dialysis Registration Package Moving Forward, As Expected
Tweet Send to a Friend
Baird maintains an 'Outperform' rating on Affymax, Inc. (NASDAQ: AFFY), PT $13.
Baird analyst says, "We continue to recommendpurchase of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "We continue to recommendpurchase of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
